Your window to real-world challenges in actual healthcare practice, from an actual healthcare practioner's’ perspective.
Why DoctoLIVE? 15 minutes of an HCP’s time booked by APLUSA to answer your practical questions live.
DoctoLIVE is your window to real-world challenges in real-life healthcare practice, from an actual healthcare practitioner's perspective.
DoctoLIVE offers you a 15-minute open discussion featuring a different HCP every session, answering your questions related to real-life treatment experiences. These discussions will be held in English.
We will cover how to implement new therapeutics in actual practice, uncover pain points and discuss areas for improvement.
“Amazed how much you can cover in 15 minutes…. Some really nice insights”
Associate Director of Business Insights and Analytics at one of the Top 10 biopharmaceutical companies
SERIES 4: Multiple Myeloma | Exclusive content based on
our MMsyndiTrack™ study
In this DoctoLIVE on Multiple Myeloma, we will rely on exclusive data from our MMsyndiTrack™ study, accompanied by Dr. Philippe RODON, who has participated in our studies for more than 10 years.
We will discuss the consequences of clinical developments in the day to day practice, the influence of new drugs on treatment, and even the future for CAR-T therapy.
Our guest is Dr. Philippe Rodon, a French Hemato-oncologist, practicing haematology at Périgueux hospital, France. He is mainly involved in the management of hematological malignancies (acute and chronic ones), especially on multiple myeloma. Dr. Rodon is a member of the french group AFM Board. He is engaged in therapeutic innovation in multiple myeloma and participated in a lot of clinical trials.
Interviewed by Siegfried ERTL from our APLUSA offices in London.
SERIES 3: Challenges in implementing new therapeutics in mRCC management
In this mRCC DoctoLIVE series, we are questioning what are challenges in implementing new therapeutics in metastatic renal cell carcinoma in 2022.
Our guest is Dr. Jean CHIDIAC, a French medical oncologist, in charge of the Oncology Unit at Louis Mourier Hospital in Colombes, France. He is co-president of the 3C. His fields of expertise are breast, kidney, urological, gynecological, ovarian, digestive, and thoracic cancers. He is also the author of several articles.
Interviewed by Geoffroy CORNETTE from our APLUSA offices in Paris.
Our guest is Dr. Arnab BASU, an academic genitourinary oncologist from UAB hospital, experienced in the use of immunotherapy and targeted therapies, with research interests in improving immunotherapies in Bladder Cancer.
Interviewed by Karen HIGGINBOTTOM from APLUSA offices in the USA.
SERIES 2: Challenges in implementing new therapeutics in advanced urothelial carcinoma management
In this first episode of Bladder Cancer DoctoLIVE series, we were questioning what the daily challenges are in implementing new therapeutics in advanced urothelial carcinoma with the participation of an American doctor.
Episode 1: Bladder Cancer USA Live Session took place on Tuesday 11th January 2022 at 5PM CET | 8AM PDT | 11AM EDT | 4PM BST.
Our guest is Dr. Arnab Basu, an academic genitourinary oncologist from UAB hospital, experienced in the use of immunotherapy and targeted therapies, with research interests in improving immunotherapies in Bladder Cancer.
Interviewed by Dr Karen HIGGINBOTTOM from our APLUSA offices in the USA.
SERIES 1: Logistics of CAR-T cell therapy in real-world practice
In Series 1, we were questioning the logistics of this revolutionary technology in cancer treatment.
Hear 5 different perspectives, with both local specificities and global commonalities. Each session provided interesting insights in 4 different countries: USA, Germany, France and the United Kingdom.
Our APLUSA expert, Dr. Karen HIGGINBOTTOM, and Dr. AKHIL, an American hemato-oncologist, were discussing how patients are considered for referral, patient eligibility to receive CAR-T therapy, barriers to treatment, unmet needs, and much more.
Dr. AKHIL is a CAR-T cell referrer in the USA. With the US being among the first to offer CAR-T cell treatment, we get insights into a market with the longest history in this field.
Our APLUSA syndicated surveys' expert Siegfried ERTL and Dr. GERL, a German hematological oncologist, were discussing how patients are considered for referral and treatment with CAR-T therapy, as well as barriers to treatment and unmet patient needs.
Dr. GERL is a hematological oncologist with an office in central Munich. He treats over 800 patients with many hematological and oncological conditions. He also holds a teaching position at the LMU in Munich. Dr. GERL has access to CAR-T treatments and regularly refers patients to a CAR-T center.
Our International Business Unit Director Charles interviewed Dr. BRAUN about the perspective of being outside a CAR-T cell therapy center, despite dealing with a lot of CAR-T eligible patients and working in a transplant center.
Dr. BRAUN is a French hemato-oncologist practicing at Avicenne Hospital based in Bobigny, France.
APLUSALIVE™ webinars present exclusive insights from recent research conducted at APLUSA, enriched with live discussions with experts, to help you understand the impact of current challenges on the healthcare market of today and tomorrow.